ArticleJournal of clinical and translational hepatology2022
Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study.
Article in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes.Hepatology international · 2023Pooled it
- Pooled it
- From NAFPD to MAFPD: a literature review of implications of a nomenclature change.Hepatobiliary surgery and nutrition · 2025Review
- Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease.Frontiers in endocrinology · 2025Article
- Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease.Clinical and experimental hepatology · 2024Article
- Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.Abdominal radiology (New York) · 2024Article
- Association between Atherogenic Dyslipidemia and Subclinical Myocardial Injury in the General Population.Journal of clinical medicine · 2024Article
- Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease among an Iranian Adult Population with Ethnic and Genetic Diversity: Results of the PolyIran-Liver Study.Middle East journal of digestive diseases · 2024Article
- [Value of constructing a non-invasive diagnostic model based on serum heme oxygenase-1 and glucose regulatory protein 78 for non-alcoholic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Article
- Relationship between skeletal muscle mass loss and metabolic dysfunction-associated fatty liver disease among Chinese patients with metabolic dysregulation.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study.Lipids in health and disease · 2023Article
- Article
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts.JHEP reports : innovation in hepatology · 2023Review
- Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD.Scientific reports · 2023Article
- The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD.Reviews in cardiovascular medicine · 2023Review
- Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.Hepatology international · 2023Article
- MAFLD: How is it different from NAFLD?Clinical and molecular hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMetabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept, proposed in 2020; however, its applicability in Asia populations has yet to be evaluated. Therefore, we aimed to compare the difference in epidemiological and clinical characteristics between MAFLD and non-alcoholic fatty liver disease (NAFLD) among Asian populations.
methodsBased on the Jinchang cohort, 30,633 participants were collected. The prevalence and incidence of MAFLD and NAFLD were used to analyze the epidemic characteristics and its overlapping effects. In addition, the corresponding clinical characteristics of the two diagnostic criteria populations were compared.
resultsThe prevalence rates of MAFLD and NAFLD were 21.03% and 18.83%, respectively. After an average 2.28-year follow-up, the incidence densities of MAFLD and NAFLD were 41.58 per 1,000 person-years and 37.69 per 1,000 person-years, respectively. With the increase of baseline age, body mass index (BMI), and waist circumference (WC) levels, the prevalence and incidence of MAFLD and NAFLD were on the rise (all
conclusionsCompared with NAFLD, the newly proposed definition of MAFLD is more practical and accurate, and it can help identify more fatty liver patients with high-risk diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.